Topic: How To Invest

Hi Pat: What is your view on Nuvo Research, now that it has received the long awaited FDA approval for its topical pain medication, combined with the deal with Covidien to market the product in the U.S.? Many thanks.

Article Excerpt

Nuvo Research, $0.31, symbol NRI on Toronto (Shares outstanding: 392.0 million; Market cap: $121.5 million), makes delivery systems that administer therapeutic drugs through the skin. The company believes this technology works with little effect on other parts of the body, because it only targets the affected area. That avoids the possible side effects of oral medication, such as high blood pressure and ulcers. Nuvo changed its name from Dimethaid in October 2005. Nuvo’s main product is Pennsaid, a lotion for arthritis pain. The company markets Pennsaid as equal to the maximum daily dose of comparable oral medication at relieving pain and stiffness associated with osteoarthritis of the knee. It also claims that Pennsaid has fewer negative side effects. Nuvo received approval from the U.S. Food and Drug Administration (FDA) to market Pennsaid on November 4, 2009. The company has now signed a license agreement with major U.S. health-care company Covidien (symbol COV on New York) to market Pennsaid in the U.S….